|Bid||70.34 x 800|
|Ask||70.13 x 1200|
|Day's Range||69.97 - 71.18|
|52 Week Range||54.32 - 74.15|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||141.64|
|Earnings Date||Jan 22, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||1.12 (1.54%)|
|1y Target Est||78.94|
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines. When President Donald Trump declared a public health emergency over the abuse of heavy-duty painkillers like oxycodone and hydrocodone, he ordered all government agencies to take action in response to the death of 70,000 Americans last year from drug overdoses. The FDA told Reuters it has received over 200 submissions from companies seeking a speedy approval process for their devices.
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.
In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.
For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.
Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.
Jim Cramer recommends stocks like Amazon and Apple in the wake of the 2018 midterm elections, in which Democrats regained control of the House of Representatives.
Although many investors like to follow equities for potential stock price increases, a large number also choose to focus on income stocks. The average S&P 500 stock dividend yield currently stands at just over 1.9%. Also, it allows for the long-term appreciation gained by investing in S&P 500 equities.
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
George Brandis, Australia’s high commissioner to the UK, said on Thursday the problem of children living on the tiny Pacific islands of Nauru and Manus island in Papua New Guinea had “largely gone away” following recent transfers to Australia. “There are hardly any children in Nauru and [Papua] New Guinea and we expect that by the end of the year there will be none,” Mr Brandis said in a radio interview. The policy U-turn by the Liberal-National coalition, which has for years refused to relocate refugee children to Australia except in emergencies, follows its drubbing in a by-election that cost it a majority in parliament.
According to a newly processed SEC filing, the firm is called Define Ventures, and it has already locked down $50 million in capital commitments from a handful of investors. Chou O'Keefe had joined Kleiner Perkins in 2013 as a partner in its small life sciences group, to focus on digital health and connected devices. Before becoming a VC, she spent six years with Abbott Vascular, a division of the health care giant Abbott, first as a global product manager and later as a global marketing director.
The U.S. Justice Department on Friday announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 by a former Abbott sales representative. AbbVie was spun out of Abbott in 2013.
Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes. The U.S. Justice Department on Friday announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 by a former Abbott sales representative.
A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, Abbott Laboratories (NYSE:ABT) has paid dividends Read More...
Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication ...
Should We Watch Abbott Laboratories in October? Abbott Laboratories’ (ABT) Medical Devices business is divided into two parts: Cardiovascular and Neuromodulation, and Diabetes Care. Cardiovascular and Neuromodulation is further divided into six reporting categories: Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation. According to the company’s third-quarter earnings conference call, Abbott Laboratories expects its Medical Devices business to have high-single-digit revenue growth YoY (year-over-year) in fiscal 2018.
Carter Worth, Cornerstone Macro, on quality bear-market stocks to buy. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.